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ABSTRACT
Introduction. Chemotherapy administered concurrently with 
radiotherapy for locally-advanced rectal cancer prior to surgery 
is a standard of care approach. A fraction of patients after chemo-
radiotherapy achieve pathological complete remission. Our aim was 
to evaluate patients treated only with a non-operative approach of 
only chemo-radiotherapy followed by observation at a community 
cancer center.
Methods. Medical charts of the patients who were treated for locally 
advanced rectal cancer and treated with chemo-radiation therapy 
alone from January 1, 2000 through May 1, 2017 at a Midwestern 
cancer center were reviewed. The clinical course of the patients was 
followed from the time of the cancer diagnosis through their last avail-
able clinical record.
Results. A series of three cases were reviewed with locally-advanced 
distal rectal cancers treated with a non-operative approach. 
Conclusions. Watchful waiting for patients with locally advanced 
distal rectal cancer who have complete clinical response with neoad-
juvant chemotherapy and radiation might be an effective treatment 
strategy. Kans J Med 2019;12(1):17-19.
INTRODUCTION
Post-operative morbidity secondary to total mesorectal excision 
in rectal cancer patients has increased the interest in organ preserv-
ing strategies significantly.1 Alternative treatment strategies without 
radical surgery not only reduces the post-operative morbidity, but 
also lowers the need for intestinal stomas and functional disorders of 
the anorectal tract.2 Several European trials have documented watch-
and-wait approaches that include treatment with chemo-radiation 
followed by regular surveillance and monitoring for tumor recur-
rence.3,4 The complete response rate with watch-and-wait approaches 
has ranged from 5 to 60%.3,4 This variation may be due to different 
follow-up durations and surveillance intensity. 
A study by Habr-Gama et al.5 reported local recurrence in 31% 
of patients with initial regrowth and late recurrences. More than 
half of the recurrences developed in the first 12 months. The authors 
described that “salvage therapy is possible in > 90% of recurrences, 
leading to 94% local disease control and 78% organ preservation”. 
The same authors conducted a prospective study on 70 patients with 
T2-T4, N0-2, M0, neoadjuvant chemo-radiotherapy that included 
54 Gy and 5-FU/leucovorin delivered in six cycles.6 Patients in this 
study were assessed for tumor response at 10 weeks from radiation 
therapy. About 47 patients had initial complete response and about 
eight patients developed regrowth in the first 12 months of follow-up. 
The aim of this case-series was to review and report the number 
of cases treated for T2-T4, N0-N2, and M0 rectal cancer with a non-
surgical approach and to evaluate the clinical outcome. Our goal was 
to augment the findings from the existing literature on the watch-and-
wait management of locally advanced distal rectal cancer patients.
METHODS
This study was a case series consisting of three patients. All of the 
patients included in the study had rectal cancer treated with chemo-
therapy and radiation with no surgical intervention. The patients were 
identified using cancer registry databases and the clinical course was 
retrospectively followed from the time of their histologically proven 
malignancy until their last available clinical record.
Medical charts of the patients who were treated for locally 
advanced rectal cancer and treated with chemo-radiation therapy 
alone from January 1, 2000 through May 1, 2017 at Our Community 
Cancer Center at Carle Foundation Hospital were reviewed. Seven-
teen patients were identified, but three presented without metastatic 
disease and were included in the case series. Patient inclusion required 
a diagnoses of rectal cancer, treated only with chemotherapy and radi-
ation and no surgical intervention. All or part of the cancer treatment 
was received at the Carle Foundation Hospital. Patients who did not 
meet the above criteria were excluded from the case-series.
The clinical course of the patients was followed from the time of 
the cancer diagnosis through their last available clinical record (Table 
1). Approval from the institutional review board committee of Carle 
Foundation Hospital was obtained prior to the study.
Table 1. Patient diagnosis, treatment regimen, and follow-up.
Patient 1 Patient 2 Patient 3
Age 93 84 65
Sex Female Male Male
State of  the disease 
upon diagnosis T3N0M0 T3N1M0 T3N1M0
Chemotherapy and 
radiation regimen
Capecitabine 
with radiation
Capecitabine 
with radiation
5FU with 
radiation
Average length of 
follow-up 24 months 24 months 30 months
RESULTS
Case 1. A 92-year-old female presented to her primary care phy-
sician with rectal bleeding. A 3 cm mass at the distal rectum was 
found on colonoscopy. Needle biopsy of the mass revealed mod-
erately differentiated rectal carcinoma at the lower rectal valve. 
Baseline computed tomography (CT) diagnostic imaging of the 
chest, abdomen, and pelvis indicated wall thickening of the distal 
rectum with no significant pelvic adenopathy and no overt findings 
for metastatic disease. The patient had T3N0M0 adenocarcinoma 
of the distal rectum by transrectal ultrasound. Based on her poor 
cardiac health due to a recent myocardial infarction and advanced 
age, the patient was regarded as high-risk for the hemicolectomy. 
She was started on capecitabine chemotherapy along with radia-
tion therapy. She completed 25 fractions of radiation therapy. A 
total of  50 Gy of radiation treatment was administered to her 
rectum. The patient tolerated the treatment well with improvement 
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continued to be in remission at 24 months post-treatment without 
evidence of metastasis on surveillance scans. 
Case 2. An 84-year-old male was found to have adenocarcinoma 
of the distal rectum after he presented with a complaint of pressure 
and discomfort with bowel movements along with intermittent rectal 
bleeding. He had a 3 cm exophytic mass in the rectum and the biopsy 
reported moderately differentiated adenocarcinoma of the rectum 
invading submucosa and muscularis propria. CT scan did not reveal 
distant metastasis. Clinical staging with the aid of transrectal ultra-
sound was determined to be cT3N1. Due to the patient’s personal 
preference, he refused surgery and wanted only non-surgical options. 
The patient was given capecitabine along with radiation therapy of 
50 Gy in 25 fractions. The patient did not have evidence of local or 
distant failure on clinical exams and surveillance studies after 36 
months post-treatment. 
Case 3. A 65-year-old male with no significant past medical 
history and no family history of colorectal cancer presented to his 
primary care provider with a complaint of intermittent rectal bleeding 
and alteration in bowel habits. He underwent colonoscopy and had a 3 
cm mid-rectal neoplasm which was hemi-circumferential, lobulated, 
ulcerated, and adjacent to the 2nd rectal valve. Biopsy demonstrated 
adenocarcinoma arising in the background of an adenomatous polyp. 
Staging CT scan of the chest, abdomen, and pelvis was unremark-
able for distant metastasis. The tumor was staged as T3N1M0 by 
transrectal ultrasound. Due to this patient’s personal preference, he 
was treated non-operatively.  He received chemotherapy with 5-fluo-
rouracil and leucovorin concurrently with radiation therapy. Thirty 
months post-treatment, he was without evidence of recurrence.
DISCUSSION
Treatment options for patients with T2-T4 colorectal cancer that 
lead to complete clinical response after neoadjuvant chemo-radio-
therapy remain controversial.2 The most common type of treatment 
is neoadjuvant chemotherapy and radiation followed by surgical man-
agement.7 The addition of chemotherapy to the neoadjuvant radiation 
has been found to improve localized disease control. Combination 
neoadjuvant treatment results in tumor downstaging, peri-rectal node 
sterilization, and preparation for surgical treatment. However, the 
absence of residual tumor cells in the resected surgical specimens 
after neoadjuvant chemoradiotherapy raised the issue of whether 
surgical treatment is necessary. This gave rise to a new treatment 
approach in patients with locally advanced rectal cancer, in which 
the patient is monitored carefully for any tumor recurrence after the 
chemo-radiation therapy. This is referred to as the strict surveillance 
method. This organ preserving strategy was designed to avoid major 
surgery which typically is associated with significant postoperative 
morbidity, functional disorders such as urinary, sexual, and anorec-
tal problems, and the need for intestinal stomas.2 Tumors that recur 
after the non-surgical approach frequently are amenable to surgical 
resection.5 
After a long debate for several years, the wait-and-watch approach 
for locally advanced rectal cancer is more well-known in the literature.5 
Trials in Europe and United States have supported the management
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of rectal cancer patients staged at T2-T3 with close surveillance 
methods using the wait-and-watch approach after receiving neo-
adjuvant chemoradiation therapy.5,8,9 These studies demonstrated 
radiological findings showing complete clinical or pathological 
response using modalities such as MRI or PET CT scans.
A study conducted by Habr-Gama et al.2 looked at the wait-and-
watch approach. In the study, patients with distal rectal cancer who 
achieved a complete clinical response with neoadjuvant chemotherapy 
and radiation were followed without undergoing any surgical manage-
ment. The patients were followed for approximately 60 months. The 
results were compared with the control group who underwent total 
mesorectal excision (TME). The patients in the wait-and-watch cat-
egory showed impressive results with five-year overall survival of 93% 
and disease-free survival of 85%.1,2 
The wait-and-watch approach has been used with selected patients 
at our cancer center, specifically for patients with locally advanced 
rectal cancer. The three patients in our case-series have shown opti-
mistic outcomes with no tumor recurrence, at least in the first 24 
months after neoadjuvant chemoradiation therapy without any sur-
gical intervention. Our study supported the findings of Maas et al.4 
who conducted a prospective study on their patients using the wait-
and-watch approach. Their study included 21 patients with locally 
advanced rectal cancer with a complete clinical response after chemo-
radiotherapy. Patients underwent surveillance follow-ups every three 
to six months using MRI, endoscopy, or CT scans. Mean follow-up was 
about 25 months. Only one patient developed local recurrence while 
the other 20 patients were alive without any signs of tumor recur-
rence. The two-year disease free survival rate for these patients was 
89% (95% CI , 43% - 98%), and the cumulative probability for two 
year overall survival was 100%. In the control group, which included 
the patients who underwent surgery after the neoadjuvant chemo-
radiotherapy, the two-year disease free survival was about 93% with 
an overall survival of 91% respectively. The three patients in our study 
also showed average overall disease free survival of 24 months with a 
two-year overall survival of 100%. 
Renehan et al.10 conducted a study in the UK of 357 patients 
with locally advanced rectal cancer; 228 of them underwent sur-
gical treatment after neoadjuvant, and the remaining 129 patients 
stayed on the wait-and-watch approach. Of these 129 patients, 44 
had local tumor regrowth and 36 patients out of 41 received a salvage 
therapy. In the matched analyses, the study did not find any difference 
in the three year overall survival (96% in the surgical vs 87% in the 
wait-and-watch group). Patients managed with wait-and-watch had 
significantly better three-year colostomy free survival than those who 
underwent surgical resection (74% vs 47%).
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To avoid the extensive procedure of abdominoperineal resec-
tion, Appelt et al.11 studied high dose radiation and chemotherapy 
in T2-T3, N0-N1 distal rectal adenocarcinomas. About 60 Gy in 30 
fractions to tumor and 50 Gy in 30 fractions to the elective lymph 
nodes were given, along with oral tegafur-uracil 300 mg/m2 every 
day for six weeks. Local recurrence rate was 15.5% (95% CI: 3.3-
26.3). The most common late toxicity observed in these patients was 
bleeding from the rectal mucosa, but overall there were no unex-
pected serious adverse effects. The study concluded that high dose 
chemo-radiotherapy and watchful waiting might be a safe alterna-
tive to abdominoperineal resection in patients with locally advanced 
distal rectal cancer.
CONCLUSIONS
Findings from several prospective trials have indicated that the 
approach of watchful waiting for patients with locally advanced 
distal rectal cancer who have shown complete clinical response 
with neoadjuvant chemotherapy and radiation might be an effective 
strategy. Our case series of three patients supported these findings. 
Our patients showed excellent response with neoadjuvant chemo-
therapy and radiation with a 100% disease free survival. The major 
limitation of our study was the small sample size and a short follow-
up period. Nevertheless, it is clear from the published prospective 
trials that the functional results after wait-and-watch treatment are 
not inferior, but rather superior to outcomes after rectal surgery. In 
future, we plan to conduct a prospective study regarding the wait-
and-watch approach for locally advanced distal rectal cancer.. 
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